- Home
- BRTX
as 12-18-2024 2:32pm EST
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | MELVILLE |
| Market Cap: | 11.3M | IPO Year: | N/A |
| Target Price: | $18.00 | AVG Volume (30 days): | 98.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.03 - $3.67 | Next Earning Date: | 11-12-2024 |
| Revenue: | $377,000 | Revenue Growth: | 189.55% |
| Revenue Growth (this year): | 482.76% | Revenue Growth (next year): | 212.24% |
Stock Insider Trading Activity of BioRestorative Therapies Inc. (NV) (BRTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Broadrick Dale | BRTX | 10% Owner | Oct 28 '24 | Sell | $1.58 | 1,112 | $1,756.96 | 445,933 |
Latest BioRestorative Therapies Inc. (NV) News
BRTX Breaking Stock News: Dive into BRTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
13 days ago
BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program
Simply Wall St.
a month ago
BioRestorative Therapies Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
GlobeNewswire
a month ago
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data
GlobeNewswire
a month ago
BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
a month ago
BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium
GlobeNewswire
a month ago
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health
GlobeNewswire
2 months ago
BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program
GlobeNewswire
2 months ago
BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events
Compare BRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BRTX BioRestorative Therapies Inc. (NV) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.